Abstract
Objective
Fibromyalgia (FM) is a syndrome expressed by chronic widespread pain often associated with reduced physical function. Exercise is a common recommendation in management of FM. We evaluated the effects of exercise training on global well-being, selected signs and symptoms, and physical function in individuals with FM.
Methods
We searched Medline, Embase, CINAHL, SportDiscus, PubMed, PEDro, and the Cochrane Central Register for Controlled Trials to July 2005 and included randomized trials evaluating cardiorespiratory endurance, muscle strength, and flexibility. Methodological quality was assessed using the van Tulder and Jadad instruments. Training protocols were evaluated using American College of Sports Medicine (ACSM) guidelines. Clinical heterogeneity limited meta-analysis to 6 aerobic and 2 strength studies.
Results
There were 2276 subjects across the 34 studies; 1264 subjects were assigned to exercise interventions. Metaanalysis of 6 studies provided moderate-quality evidence that aerobic-only exercise training at ACSM-recommended intensity levels has positive effects on global well-being (SMD 0.49, 95% CI 0.23–0.75) and physical function (SMD 0.66, 95% CI 0.41–0.92) and possibly on pain (SMD 0.65, 95% CI –0.09 to 1.39) and tender points (SMD 0.23, 95% CI –0.18 to 0.65). Strength and flexibility remain underevaluated; however, strength training may have a positive effect on FM symptoms.
Conclusion
Aerobic-only training has beneficial effects on physical function and some FM symptoms. Strength-only training may improve FM symptoms, but requires further study. Large, high-quality studies of exercise-only interventions that provide detailed information on exercise prescription and adherence are needed.
Key Indexing Terms:Footnotes
-
A.J. Busch, PhD, Associate Professor, Director, School of Physical Therapy; C.L. Schachter, PhD, Adjunct Professor, School of Physical Therapy, University of Saskatchewan; T.J. Overend, PhD, Associate Professor, School of Physical Therapy, University of Western Ontario, London, Ontario; P.M. Peloso, MD, Director, Clinical Immunology, Analgesia, Anemia, and Urology, Clinical Development, Merck Research Laboratories, Merck & Co.; K.A.R. Barber, MSc, Director of Quality Improvement, Saskatchewan Health Quality Council.
-
Based on a Cochrane Review published in The Cochrane Library 2007, Issue 4 (see www.thecochranelibrary.com for information). Cochrane Reviews are regularly updated as new evidence emerges and in response to feedback and The Cochrane Library should be consulted for the most recent version of the review.
